SNTI

Company Overview — What Does Senti Biosciences, Inc. Do?

Dynamics Special Purpose Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in Redwood City, California. Senti Biosciences, Inc. (SNTI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Timothy K. Lu and employs approximately 4 people. With a market capitalization of $26M, SNTI is one of the notable companies in the Healthcare sector.

Senti Biosciences, Inc. (SNTI) Stock Rating — Avoid (April 2026)

As of April 2026, Senti Biosciences, Inc. receives a Avoid rating with a composite score of 18.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.SNTI ranks #4,354 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Senti Biosciences, Inc. ranks #802 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SNTI Stock Price and 52-Week Range

Senti Biosciences, Inc. (SNTI) currently trades at $0.86. The stock lost $0.01 (0.6%) in the most recent trading session. The 52-week high for SNTI is $5.10, which means the stock is currently trading -83.1% from its annual peak. The 52-week low is $0.80, putting the stock 7.9% above its annual trough. Recent trading volume was 41K shares, suggesting relatively thin trading activity.

Is SNTI Overvalued or Undervalued? — Valuation Analysis

Senti Biosciences, Inc. (SNTI) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.79x, versus the sector average of 2.75x. The price-to-sales ratio is 304.37x, compared to 1.66x for the average Healthcare stock.

At current multiples, Senti Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Senti Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Senti Biosciences, Inc. (SNTI) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1356.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -148.0% versus the sector average of -33.1%.

The operating margin is -312631.8% (sector: -66.1%). Net profit margin stands at -279263.6%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SNTI Debt, Balance Sheet, and Financial Health

Senti Biosciences, Inc. has a debt-to-equity ratio of 816.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.67x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $12M.

SNTI has a beta of 1.14, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Senti Biosciences, Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Senti Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Senti Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.73. Net income for the quarter was $-76M. Operating income came in at $-65M.

In FY 2025, Senti Biosciences, Inc. reported revenue of $22,000 and earnings per share (EPS) of $-2.73. Net income for the quarter was $-61M. Operating income came in at $-69M.

In Q3 2025, Senti Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.69. Net income for the quarter was $-18M. Operating income came in at $-17M.

In Q2 2025, Senti Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.56. Net income for the quarter was $-15M. Operating income came in at $-17M.

Over the past 8 quarters, Senti Biosciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing SNTI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SNTI Dividend Yield and Income Analysis

Senti Biosciences, Inc. (SNTI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SNTI Momentum and Technical Analysis Profile

Senti Biosciences, Inc. (SNTI) has a momentum factor score of 14/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.

SNTI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Senti Biosciences, Inc. (SNTI) ranks #802 out of 838 stocks based on the Blank Capital composite score. This places SNTI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SNTI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SNTI vs S&P 500 (SPY) comparison to assess how Senti Biosciences, Inc. stacks up against the broader market across all factor dimensions.

SNTI Next Earnings Date

No upcoming earnings date has been announced for Senti Biosciences, Inc. (SNTI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SNTI? — Investment Thesis Summary

The quantitative profile for Senti Biosciences, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 14/100, a headwind for near-term performance. High volatility (stability score 26/100) increases portfolio risk.

In summary, Senti Biosciences, Inc. (SNTI) earns a Avoid rating with a composite score of 18.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SNTI stock.

Related Resources for SNTI Investors

Explore more research and tools: SNTI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SNTI head-to-head with peers: SNTI vs AZN, SNTI vs SLGL, SNTI vs VMD.